Copy to clipboard 
Wright Medical reported 3Q19 revenue of USD $212.4 million, +9.4% vs. 3Q18.
- On November 4, 2019, Wright Medical announced that it had reached a definitive agreement to be purchased by Stryker with the deal expected to close in 2H20
- The 3Q19 was the second consecutive quarter of growth deceleration for Wright Medical
- The company has recently faced severe disruption to its legacy Cartiva sales distributors, as well as talent retention challenges with smaller competitors increasingly penetrating Wright’s core foot and ankle business
- ORTHOWORLD projects Wright Medical full year 2019 revenue of $899.6 million, +7.6% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Reconstruction Extremities | $106.7 | $94.0 | $12.7 | 13.5% |
| Trauma | $74.2 | $68.1 | $6.1 | 8.9% |
| Sports Medicine | $4.4 | $4.8 | ($0.4) | (8.9%) |
| Orthobiologics | $27.2 | $27.2 | $0.0 | 0% |
| Total | $212.4 | $194.1 | $18.3 | 9.4% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Reconstruction Extremities | $338.7 | $291.7 | $47.0 | 16.1% |
| Trauma | $235.4 | $214.3 | $21.1 | 9.8% |
| Sports Medicine | $14.0 | $14.6 | ($0.7) | (4.6%) |
| Orthobiologics | $84.3 | $77.4 | $6.9 | 8.9% |
| Total | $672.3 | $598.0 | $74.3 | 12.4% |
Geographic Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $162.2 | $145.6 | $16.7 | 11.4% |
| Ex-US | $50.2 | $48.5 | $1.7 | 3.4% |
| EMEA | $35.1 | $33.7 | $1.4 | 4.2% |
| Asia Pacific | $10.5 | $10.2 | $0.3 | 3.4% |
| Rest of World | $4.5 | $4.6 | ($0.1) | (2%) |
| Total | $212.4 | $194.1 | $18.3 | 9.4% |
Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $212.4 | |
| Cost of Sales | ($44.4) | 20.9% |
| General and Admin | ($152.8) | 71.9% |
| R & D | ($18.0) | 8.5% |
| Other | ($41.0) | 19.3% |
| Net Earnings | ($43.8) | (20.6%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Wright Medical reported 3Q19 revenue of USD $212.4 million, +9.4% vs. 3Q18.
On November 4, 2019, Wright Medical announced that it had reached a definitive agreement to be purchased by Stryker with the deal expected to close in 2H20
The 3Q19 was the second consecutive quarter of growth deceleration for Wright Medical
The company...
Wright Medical reported 3Q19 revenue of USD $212.4 million, +9.4% vs. 3Q18.
- On November 4, 2019, Wright Medical announced that it had reached a definitive agreement to be purchased by Stryker with the deal expected to close in 2H20
- The 3Q19 was the second consecutive quarter of growth deceleration for Wright Medical
- The company has recently faced severe disruption to its legacy Cartiva sales distributors, as well as talent retention challenges with smaller competitors increasingly penetrating Wright’s core foot and ankle business
- ORTHOWORLD projects Wright Medical full year 2019 revenue of $899.6 million, +7.6% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Reconstruction Extremities | $106.7 | $94.0 | $12.7 | 13.5% |
| Trauma | $74.2 | $68.1 | $6.1 | 8.9% |
| Sports Medicine | $4.4 | $4.8 | ($0.4) | (8.9%) |
| Orthobiologics | $27.2 | $27.2 | $0.0 | 0% |
| Total | $212.4 | $194.1 | $18.3 | 9.4% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Reconstruction Extremities | $338.7 | $291.7 | $47.0 | 16.1% |
| Trauma | $235.4 | $214.3 | $21.1 | 9.8% |
| Sports Medicine | $14.0 | $14.6 | ($0.7) | (4.6%) |
| Orthobiologics | $84.3 | $77.4 | $6.9 | 8.9% |
| Total | $672.3 | $598.0 | $74.3 | 12.4% |
Geographic Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $162.2 | $145.6 | $16.7 | 11.4% |
| Ex-US | $50.2 | $48.5 | $1.7 | 3.4% |
| EMEA | $35.1 | $33.7 | $1.4 | 4.2% |
| Asia Pacific | $10.5 | $10.2 | $0.3 | 3.4% |
| Rest of World | $4.5 | $4.6 | ($0.1) | (2%) |
| Total | $212.4 | $194.1 | $18.3 | 9.4% |
Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $212.4 | |
| Cost of Sales | ($44.4) | 20.9% |
| General and Admin | ($152.8) | 71.9% |
| R & D | ($18.0) | 8.5% |
| Other | ($41.0) | 19.3% |
| Net Earnings | ($43.8) | (20.6%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
